Servier’s $1.55B Edgewise acquisition backfires after Phase 3 setback
French pharmaceutical group Servier has suffered a major setback just four months after completing its $1.55 billion upfront acquisition of Edgewise Therapeutics' muscular dystrophy business. Sevasemten, the centerpiece of the deal, has failed its pivotal trial in Becker muscular dystrophy, despite encouraging results from earlier studies.
Why it matters: Servier acquired the muscular dystrophy business from U.S.-based Edgewise Therapeutics in June, paying $1.55 billion upfront (approximately €1.3 billion), with another $1.1 billion (approximately €950 million) tied to regulatory and commercial milestones. The transaction, completed July 13, was intended to accelerate Servier’s expansion into rare neurological diseases.
Less than four months later, the asset underpinning that strategy has delivered a disappointing readout.
The results: The 18-month, placebo-controlled GRAND CANYON study, which enrolled 175 adults with Becker muscular dystrophy, failed to meet its primary endpoint of improvement on the North Star Ambulatory Assessment (NSAA), a 17-item scale measuring patients’ ability to perform activities such as walking, standing and climbing stairs.
Secondary endpoints were also missed, although Servier reported that sevasemten maintained a favorable safety and tolerability profile.
The company has not disclosed detailed efficacy data and is conducting a broader analysis of the results.
The surprise: The failure contrasts with positive results reported in December 2024 from the Phase 2 CANYON study, which helped build confidence in the drug before the acquisition.
That trial met its primary endpoint, showing a statistically significant reduction in creatine kinase (CK), a biomarker of muscle damage. Sevasemten also reduced another muscle injury marker, TNNI2, by 77%.
More importantly for patients, the treatment group maintained stable NSAA scores over 12 months, while the placebo group declined. However, the difference between groups on this functional measure did not reach statistical significance (p=0.16), suggesting a possible benefit that the Phase 2 study could not establish conclusively.
Longer-term observations from the MESA open-label extension further suggested that sevasemten could stabilize muscle function for several years. Unlike GRAND CANYON, however, those findings were not based on a concurrent placebo-controlled comparison.
How it works: Becker muscular dystrophy is a rare inherited disorder caused by mutations affecting dystrophin, a protein that helps protect muscle fibers from damage. The disease causes progressive muscle weakness and loss of mobility, and no treatment is specifically approved for Becker muscular dystrophy.
Sevasemten is an oral fast skeletal myosin inhibitor designed to protect vulnerable muscles from contraction-induced damage rather than correcting the underlying genetic defect.
What’s next: The setback also raises questions about sevasemten’s future in Duchenne muscular dystrophy, a more severe form of the disease in which the drug is being investigated in Phase 2 studies.
Servier has not announced whether the Becker results will affect its Duchenne development plans. According to its press release, the company is analyzing the data to understand what the findings mean.
The bottom line: Servier acquired sevasemten shortly before its decisive clinical test, betting that promising early results would translate into a viable treatment. The failure now casts doubt on the value of one of its largest recent investments in rare neurology, while leaving the drug’s future in both Becker and Duchenne muscular dystrophy uncertain.
